Ara-290

What It Is

Ara-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heterodimer of the EPO receptor and the beta common receptor (βcR). Unlike EPO, Ara-290 does not stimulate erythropoiesis or increase red blood cell production, avoiding the thrombotic and cardiovascular risks associated with EPO therapy. Instead, it targets tissue repair, anti-inflammatory, and neuroprotective pathways. Clinical trials have been conducted in type 2 diabetes-related neuropathy, sarcoidosis, and chronic pain. A Phase II trial in patients with type 2 diabetic neuropathy demonstrated improvements in corneal nerve fiber density and small nerve fiber function. A separate Phase II study in sarcoidosis showed improvements in quality of life measures and reductions in fatigue. Ara-290's mechanism through the innate repair receptor is mechanistically distinct from all other neuroprotective peptides, targeting a non-hematopoietic EPO signaling pathway that promotes tissue repair without erythropoietic side effects. As of 2026, development has slowed and no Phase III trials have been initiated, though the compound remains of research interest for its novel mechanism of action. Ara-290 is not FDA-approved for any indication.

Why Researchers Study It

Ara-290 represents a novel pharmacological approach — isolating the tissue-protective and anti-inflammatory properties of EPO signaling from its hematopoietic effects. Its selective activation of the innate repair receptor opens a unique therapeutic window for neuropathy, chronic inflammatory conditions, and tissue repair without the cardiovascular risks of EPO.

Proposed Mechanisms

• Selectively activates the innate repair receptor (IRR), a heterodimer of EPO receptor and beta common receptor
• Does not stimulate erythropoiesis or increase red blood cell count
• Promotes Schwann cell survival and nerve fiber regeneration
• Anti-inflammatory effects through modulation of macrophage phenotype
• Cytoprotective signaling in metabolically stressed tissues

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Ara-290 compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Brines M. et al. — ARA 290, a non-erythropoietic peptide. Mol Med. 2015 PubMed

Related Peptides